Evidence map›Paper›PMID 38817857›Full record

ReviewJournal of Cancer2024

Revisiting Temozolomide's role in solid tumors: Old is gold?

Dimitrios Matthaios, Ioanna Balgkouranidou, Konstantinos Neanidis, Andreas Sofis, Anastasia Pikouli, Konstantinos Romanidis, Aglaia Pappa, Michael Karamouzis, Anna Zygogianni, Charalampos Charalampidis and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dimitrios MatthaiosDepartment of Oncology, General Hospital of Rhodes, Rhodes, Greece.
Ioanna BalgkouranidouDepartment of Oncology, Democritus University of Thrace, Alexandroupolis, Greece.
Konstantinos NeanidisOncology Department, 424 General Military Training Hospital, Thessaloniki, Greece.
Andreas SofisAttikon University Hospital, Athens, Greece.
Anastasia PikouliThird Department of Surgery, Attikon University Hospital, Athens, Greece.
Konstantinos RomanidisSecond Department of Surgery, University General Hospital of Alexandroupolis, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
Aglaia PappaDepartment of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
Michael KaramouzisMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Anna ZygogianniRadiation Oncology Unit, 1st Department of Radiology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Charalampos CharalampidisPathology Department, University of Cyprus, Cyprus.
Paul ZarogoulidisPulmonary-Oncology Department, General Clinic Euromedice, Thessaloniki, Greece.
George RigasOncology Department, Private General Clinic of Volos, Volos, Greece.
Alex GalanisDepartment of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Temozolomide is an imidazotetrazine with a long history in oncology especially for the high grade malignant glioma and metastatic melanoma. However, last year's new indications for its use are added. Its optimum pharmacodynamic profile, its ability to penetrate the blood-brain barrier, the existence of methylation of MGMT in solid tumors which enhances its efficacy, the identification of new agents that can overcome temozolomide's resistance, the promising role of temozolomide in turning immune cold tumors to hot ones, are leading to expand its use in other solid tumors, giving oncologists an additional tool for the treatment of advanced and aggressive neoplasms.

Indexed as

solid tumorstemozolomide

Identifiers

PMID38817857
PMCPMC11134434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.